IRIS
DI BENEDETTO, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.837
AS - Asia 2.206
EU - Europa 2.073
SA - Sud America 205
AF - Africa 36
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.367
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.775
SG - Singapore 955
IE - Irlanda 535
CN - Cina 484
RU - Federazione Russa 439
SE - Svezia 224
HK - Hong Kong 211
VN - Vietnam 207
TR - Turchia 198
IT - Italia 195
BR - Brasile 181
DE - Germania 174
UA - Ucraina 131
GB - Regno Unito 119
FR - Francia 81
FI - Finlandia 61
IN - India 49
CA - Canada 38
NL - Olanda 31
BE - Belgio 28
JP - Giappone 21
MX - Messico 13
BD - Bangladesh 12
ID - Indonesia 11
PL - Polonia 11
ZA - Sudafrica 11
ES - Italia 9
IQ - Iraq 9
AR - Argentina 8
CZ - Repubblica Ceca 8
EC - Ecuador 7
KR - Corea 6
DZ - Algeria 5
LT - Lituania 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AT - Austria 4
AU - Australia 4
JM - Giamaica 4
LB - Libano 4
PK - Pakistan 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
CH - Svizzera 3
EG - Egitto 3
EU - Europa 3
JO - Giordania 3
KW - Kuwait 3
MA - Marocco 3
MK - Macedonia 3
PH - Filippine 3
CI - Costa d'Avorio 2
CO - Colombia 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
RO - Romania 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
IR - Iran 1
KE - Kenya 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
TH - Thailandia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 8.367
Salva come PNG Salva come JPEG
Città #
Chandler 603
Dublin 535
Jacksonville 530
Singapore 521
San Jose 351
Ashburn 258
Dallas 215
Hong Kong 207
Santa Clara 177
Boardman 148
Izmir 137
New York 111
The Dalles 103
Ann Arbor 95
Beijing 94
L'aquila 82
Nanjing 80
Lawrence 75
Moscow 75
Princeton 75
Ho Chi Minh City 65
Wilmington 63
Los Angeles 53
San Mateo 44
Dearborn 42
Hanoi 41
Council Bluffs 37
Woodbridge 35
Nanchang 31
Amsterdam 29
Dong Ket 26
L’Aquila 26
Lauterbourg 25
Milan 25
Brussels 24
Munich 24
Columbus 23
Helsinki 22
São Paulo 22
Hefei 21
Shanghai 21
Tokyo 21
Verona 19
Seattle 17
Kunming 16
Mountain View 16
Shenyang 16
Orem 15
Jiaxing 14
Chennai 13
Des Moines 12
Haiphong 12
Houston 12
Montreal 12
Frankfurt am Main 11
Hebei 11
Zhengzhou 11
Johannesburg 10
Pune 10
Tianjin 10
Warsaw 10
Changsha 9
Chicago 9
Ningbo 9
Stockholm 9
Grafing 8
Jinan 8
Norwalk 8
San Francisco 8
Guangzhou 7
Jakarta 7
Mumbai 7
Phoenix 7
Poplar 7
Brno 6
London 6
Manchester 6
Rio de Janeiro 6
Rome 6
Toronto 6
Atlanta 5
Bremen 5
Denver 5
Edinburgh 5
Hangzhou 5
Lanzhou 5
Nuremberg 5
Pescara 5
Ankara 4
Brasília 4
Da Nang 4
Erbil 4
Falkenstein 4
Fremont 4
Leuven 4
Madrid 4
Mexico City 4
New Delhi 4
Ottawa 4
Paris 4
Totale 5.666
Salva come PNG Salva come JPEG
Nome #
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 175
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 154
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 153
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 152
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 151
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 149
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 149
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 148
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 147
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 145
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 138
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 136
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 136
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 135
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 135
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 133
Cardiovascular disease in primary sjögren’s syndrome 130
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 130
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 127
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 127
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 126
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 125
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 125
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 125
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 121
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 121
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 120
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 120
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 117
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 117
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 117
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 116
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 115
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 114
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 114
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 113
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 112
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 111
Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases 110
Interstitial lung disease in systemic sclerosis: current and future treatment. 110
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 108
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al 108
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 107
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 106
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 106
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 106
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 105
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 105
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 104
Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: A pilot study 104
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 104
Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study 103
The Vessels Contribute to Fibrosis in Systemic Sclerosis 103
Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis 102
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 101
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 99
Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort 99
Cellular players in angiogenesis during the course of systemic sclerosis. 98
FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis 98
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 95
Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC) 93
Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC). 89
Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives 89
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome 88
Association between clinical, histopathological and molecular features in primary Sjogren's Syndrome: a retrospective study 86
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 85
Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF 85
Mesenchymal stem cells transplantation in Systemic Sclerosis: comment on the article by ATJ Maria et al 84
THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers 83
Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2 83
VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION. 79
 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 74
Potential of stem cells in the treatment of rheumatic disease 73
SAT0641 Performance and agreement of different operators and histological techniques for the assessment of germinal centres in minor salivary glands in primary sjÖgren’s syndrome 68
Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor 66
Phenotypical and functional characteristics of in vitro-expanded adipose-derived mesenchymal stromal cells from patients with systematic sclerosis 63
Totale 8.548
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021190 0 0 0 0 0 0 0 0 0 26 114 50
2021/2022457 25 16 97 38 11 10 4 24 33 38 37 124
2022/20231.580 113 115 29 199 108 166 2 95 675 12 46 20
2023/2024377 60 21 21 29 35 132 9 16 1 15 4 34
2024/20251.492 38 28 146 56 230 121 165 92 330 69 119 98
2025/20262.542 198 260 143 313 282 208 472 92 255 319 0 0
Totale 8.548